Daclizumab
Daclizumab is a humanized mAb against CD25 (interleukin-2R-α), which is expressed on immune cells. Mechanisms by which daclizumab exerts therapeutic effects in MS are incompletely understood, but one important mechanism is through the profound expansion of regulatory CD56 natural killer cells. Daclizumab is not yet approved for use in RRMS, but has had successful phase II and III trials.